GO
Loading...

Medicine

More

  • Aug 28- OncoMed Pharmaceuticals Inc said the U.S. Food and Drug Administration lifted a partial hold on patient enrolments for three trials testing its experimental cancer drug, vantictumab.

  • US to begin safety testing Ebola vaccine next week Thursday, 28 Aug 2014 | 8:43 AM ET

    The National Institutes of Health announced Thursday that it is launching the safety trial on a vaccine developed by the agency's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline.

  • Human trials of Ebola vaccine to start next week Thursday, 28 Aug 2014 | 8:09 AM ET
    Medicins Sans Frontieres health workers at an isolation camp in Liberia during the visit of the UN Ebola systems coordinator, Aug. 23, 2014.

    The trials will start at the NIH in Maryland. A vaccine is "the first step in a long process" to control Ebola, Dr. Anthony Fauci says. NBC reports.

  • WHO says Ebola outbreak could strike 20,000 people Thursday, 28 Aug 2014 | 6:00 AM ET

    GENEVA, Aug 28- The current Ebola outbreak in West Africa could infect more than 20,000 people, the World Health Organisation said on Thursday in a bleak assessment of the deadly disease.

  • LAUNCESTON, Australia, Aug 28- The resource boom is often cast as both villain and hero in Australia, being simultaneously recognized as a major driver of the country's wealth but also as a destroyer of traditional industries.

  • Venezuela battles obesity amid dearth of good food Wednesday, 27 Aug 2014 | 12:13 AM ET

    BOGOTA, Colombia— Venezuela's socialist government is sounding the alarm about growing waistlines in a country where record food shortages are making it harder to put healthy meals on the table, prompting many people to fill up on empty calories.

  • WASHINGTON, Aug 26- A new method for removing allergens from peanuts means help could soon be on the way for the roughly 2.8 million Americans with a potentially life-threatening allergy to the popular food, the U.S. Department of Agriculture said on Tuesday.

  • WASHINGTON, Aug 26- A new method for removing allergens from peanuts means help could soon be on the way for the roughly 2.8 million Americans with a potentially life-threatening allergy to the popular food, the U.S. Department of Agriculture said on Tuesday.

  • Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.

  • Ebola is 'contained' in Nigeria: Health minister Tuesday, 26 Aug 2014 | 12:05 PM ET
    A pharmacist searches for drugs in a pharmacy in Lagos, Nigeria, July 26, 2014.

    Nigeria's health minister has insisted the Ebola outbreak has been contained in the country.

  • Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in the hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.

  • Ahead of the Bell: Kite Pharma shares jump Tuesday, 26 Aug 2014 | 8:42 AM ET

    Shares of Kite Pharma surged before markets opened Tuesday after the drug developer detailed promising results for its most advanced product, a potential treatment for an aggressive form of non-Hodgkin's lymphoma.

  • Aug 25- Drug developer Kite Pharma Inc said its experimental cancer immunotherapy showed potential in treating patients with an aggressive form of blood cancer, in an early-stage study. In one arm of the study, funded by Kite and conducted by National Cancer Institute, 15 patients were given the therapy.

  • BUZZ-: KITE PHARMA INC: LEAD CANCER DRUG SHOWS PROMISE IN. **Cancer drug developer's shares up 31.2 pct at $29.25 in extended trade. **Says its lead drug has potential to treat aggressive form of blood cancer.

  • Aug 25- Drug developer Kite Pharma Inc said its experimental cancer therapy showed potential in treating patients in an early-stage study. The company's lead drug, KTE-C19, is being developed to fight an aggressive form of blood cancer. Kite's shares were up 35.2 percent at $33.33 in extended trading.

  • WINNIPEG, Manitoba, Aug 25- Four monkeys survived the Ebola virus after being injected with a vaccine that included Immunovaccine Inc's technology, the tiny Canadian company said on Monday, and the announcement sent its stock soaring.

  • Roche's blockbuster pharma deal     Monday, 25 Aug 2014 | 3:47 PM ET

    CNBC's Meg Tirrell breaks down the mega deal between Swiss pharmaceutical firm Roche and InterMune for $8.3 billion.

  • Aug 25- Four monkeys survived the Ebola virus after being injected with Immunovaccine Inc's experimental vaccine, the tiny Canadian company said on Monday, an announcement that sent its stock soaring. The tests were performed by the U.S. Health Department's National Institutes of Health, based in Maryland.

  • Roche CEO: InterMune perfect strategic fit     Monday, 25 Aug 2014 | 11:18 AM ET

    CNBC's Meg Tirrell speaks to Roche CEO Severin Schwan, and InterMune CEO Daniel Welch, about Roche's $8.3 billion acquisition of InterMune and the opportunity for the drug Esbriet in the U.S.

  • FDA names potential Insys treatment an orphan drug Monday, 25 Aug 2014 | 10:17 AM ET

    A potential treatment from Insys Therapeutics Inc. for an aggressive form of brain cancer will have some marketing exclusivity if regulators eventually approve it. The Food and Drug Administration has granted an orphan drug designation to the Chandler, Arizona, drugmaker's pharmaceutical cannabidiol, or CBD.